Podcasts about top takeaways

In this PrimeVP Podcast episode, we go back to the roots of the internet with Sabeer Bhatia, the man who gave the world Hotmail.

Send us a textAre you tired of writing one-off blog posts and constantly hunting for the next client? In this episode of The Savvy Scribe Podcast, we're talking about what it really takes to grow your writing business beyond freelancing.You'll learn how to shift from being “just” a freelance writer to building a sustainable, scalable writing business. From bundling services to exploring digital products and refining your niche, this episode is full of practical ideas you can use right away.Top Takeaways to Elevate Your Writing BusinessHow to productize your writing servicesThe truth about selling digital productsThe power of validationWhy bundling services worksFinding your niche—and owning itHow to create consistent incomeThis episode is especially helpful if you're feeling stuck, burned out, or ready to do more than just write blog posts. There's so much opportunity in the writing business space—you just need the strategy to get there.Welcome to the Savvy Scribe Podcast, I'm so glad you're here! Before we start the show, if you're interested, we have a free Facebook group called "Savvy Nurse Writer Community"I appreciate you following me and listening today. I would LOVE for you to subscribe: ITUNESAnd if you love it, can I ask for a

In the first part of my interview with Guest Winnona, we talked about the big health changes she experienced on a whole food plant-based diet over the course of a year. Now in this 2nd Interview part, we get practical.  Winnona not only shares what her typical meals are like, but also more meal ideas and some practical low-oil cooking tips in the plant-based kitchen. In this episode, Winnona also gives us a key takeaway piece of advice to help those of us in the midst of our plant-based diet journeys or about to start one. Don't miss this episode!   Join -> Plant-Powered Life Transformation Course: www.plantnourished.com/ppltcourse Contact -> healthnow@plantnourished.com Learn -> www.plantnourished.com Connect with Community -> www.facebook.com/groups/beginnerplantbaseddietsuccess Get Free 15-Minute Strategy Call -> www.plantnourished.com/strategycall Free Resource -> Quick Start Grocery Guide for Plant-Based Essentials: www.plantnourished.com/groceryguide     Have a question about plant-based diets that you would like answered on the Plant Based Eating Made Easy Podcast? Send it by email (healthnow@plantnourished.com) or submit it by a voice message here: www.speakpipe.com/plantnourished     [Plantbased Eating, Plant Based, Gut Health, Diabetes, Blood Sugars, Blood Glucose Control, High Cholesterol, Diabetes, Keto, Plantbased Transition, Heart Health, Heart Disease, Gut Issues, Weight Loss, Whole Foods, High Blood Pressure, Hypertension, Lose Weight, Drop Pounds, Meal Ideas, Transition Tips, Quick Meals, Plant Based Meals]

We're celebrating 100 episodes of the Hit Record Podcast with a special roundtable discussion featuring Meredith Olmstead, Nida Ajaz, Kristin Mock, and Sophie Bawany. From how the podcast started to our team's favorite episodes over the years, we're reflecting on the trends that haven't changed—and the tactics that still move the needle for credit unions and banks. Whether it's email strategy, branded search ads, or being human on social media, this episode is packed with timeless insights for financial marketers.Key Takeaways:Some lessons are evergreen. Branded keyword strategy, personalized emails, and authentic social media have all evolved, but they're still as critical in 2025 as they were in 2021.Short, implementable content wins.  The Hit Record Podcast was created to offer quick, actionable tips for busy financial marketers. That approach still resonates today.Human connection is still the difference. Even in an AI-driven world, authenticity and trust remain the best ways to engage, convert, and retain members.

On this edition of the Autzen Audibles Podcast, Jared Mack gives his goodbyes to the beat as he begins a new career. We end the show with our top takeaways from the Ducks' fall camp following its conclusion. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Football season is here, and Ray, JayRich, and guest Derek Brown (@DBRo_FFB) break down all the biggest storylines from NFL preseason week 2! We react to Caleb Williams' strong showing, rookie RB performances from Ashton Jeanty, Omarion Hampton, and others, and dive into QB battles with Jackson Dart, Dylan Gabriel, our thoughts on Cam Ward and more. Plus, what do Justin Fields' struggles mean for Garrett Wilson, and how should you value Rashee Rice with a looming suspension? All this and more on today's Wake Up show! Thank you for checking out the Podcast, be sure to follow and comment if you have any questions, we are always happy to answer any. For Access to our Premium Tools (Trinity, WAR & More) & Discord Community ⁠https://ddfantasyfootball.com/subscriptions/⁠ Subscribe to the Youtube Channel DDFFB ⁠https://www.youtube.com/@DDFFB⁠ Subscribe to Ray's Channel: ⁠https://www.youtube.com/@RayGQue⁠ Check out All of Ray's Articles at Yahoo!: ⁠https://sports.yahoo.com/author/ray-garvin/⁠ Follow Ray on Bleacher Report: ⁠https://br.app.link/7ExIDsWfHVb⁠

Kainani Stevens, John Oehser, and Brian Sexton are live with Jags A.M. to recap Preseason Week 2 against the New Orleans Saints. They point out an increased physicality at the line of scrimmage that resulted in an effective run game. Rookie RB Bhayshul Tuten earned his second rushing touchdown of the preseason yesterday. The crew ends the show by dishing out some hot takes.See omnystudio.com/listener for privacy information.

Ever feel like your partner's mood completely hijacks yours? In this episode, Stephanie breaks down the mindset shift that will change how you show up in tense moments and how to become the emotionally grounded man your partner needs when conflict arises.✅ Top Takeaway #1: Matching her negative energy only fuels the disconnect. Instead, choose to be the calm, secure presence in the room.✅ Top Takeaway #2: "Hug the porcupine", lean into love even when she's bristly. That's real masculine leadership.✅ Top Takeaway #3: Your emotions are yours to command. You don't have to react; you get to choose how to respond, especially in love.Ready to improve your sex life? Apply to work with me: https://www.stephanieganowski.com/coaching-application-video/

Some teams reach a point where the leader can step out of production without losing momentum. That usually takes years, but in under five, Brian Buckley grew his team from just a few agents to 35 and positioned himself to focus solely on building the business. From his background in construction and development to leading one of the top teams at his brokerage, Brian has made systems, culture, and accountability non-negotiables. He put platforms like Sisu, Follow Up Boss, and Battr in place early, not after growth happened, but to drive it. “If I can control mortgage, title, and everything that can blow up a deal, I've got a much higher chance of getting it to the finish line,” says Brian. In this episode, Brian Charlesworth talks with Brian about building a team that can scale without the leader in production, why controlling the client experience matters, and how data-driven coaching can turn weaknesses into wins. Culture plays a big role in how his team runs. He calls out toxic behavior quickly, encourages daily “win of the day” updates, and makes sure agents back each other up without ego. Performance data is visible in the office for everyone to see, creating a natural level of ownership. “My job is technology and leads. Your job is closing deals and building our brand forward-facing,” he explains. That clarity has fueled growth, along with smart recruiting. Brian openly shares what works in the brokerage community, believing that value given comes back in results. Moving into Zillow Flex and integrating Battr for automated follow-ups has helped keep leads from slipping away while freeing him from daily chasing.   Top Takeaways:   (1:27) Sisu as a growth driver from day one (4:22) Why experienced agents return to teams (6:45) Cutting toxicity and building real teamwork (8:34) Recruiting by sharing what works (11:35) Controlling the process to close more deals (16:26) Treating agents like partners (17:34) Coaching agents into ownership (19:36) Using automation to boost follow-up (23:50) Lower costs, higher ROI with the right tools (27:08) Turning “bad” leads into closings (30:05) Winning deals with smart concessions (31:51) Skiing adventures beyond real estate   Listen in to learn how to scale a real estate business with systems, protect culture as you grow, and free yourself from the day-to-day without losing momentum.   About Brian Buckley   Brian M. Buckley is with LoKation Real Estate in Pompano Beach, FL, and has worked in real estate for over 25 years across Georgia and South Florida. He studied Communications and Advertising at the University of Georgia before moving into residential home building and commercial real estate. Today, he focuses on helping clients with their home buying needs and draws on decades of industry experience. Outside of work, Brian enjoys snow skiing, scuba diving, and spending time in Lake Tahoe with his fiancée Terra and their dog Jennifur.   Connect with Brian: LinkedIn

Alex Dunlap, Trashman and Cody Carpentier go over their biggest fantasy football takeaways from Week 1 of NFL preseason action. Get the Magical, Mystical, MYTHICAL Cheat Sheet Products at https://rosterwatch.com/buy-rosterwatch-pro----------------Join RosterWatch Nation TODAY to support your boys.Go PREMIUM for Weekly, Dynasty and Best Ball Rankings plus DFS Tools and MORE -- https://rosterwatch.com/buy-rosterwatch-proFollow us on Twitter -- https://www.x.com/RosterWatchFollow on Instagram -- https://www.instagram.com/rosterwatch/----------------RosterWatch is your year-round source for the best Fantasy Football analysis, including updates LIVE from Training Camp, The NFL Combine, Pro Days, and the Senior Bowl and Shrine Bowl.----------------Subscribe to the podcast:iTunes -- https://podcasts.apple.com/us/podcast/rosterwatch-podcast/id493875129?mt=2Spotify -- https://open.spotify.com/show/2jWDOZcppg9uYVaAWA7YdM?si=0b9aeaa77ae24316&nd=1&dlsi=1b5923c3f21b43c7iHeartRadio -- https://www.iheart.com/podcast/269-rosterwatch-podcast-48874884/RosterWatch PRO offers the best toolset available to help you win your fantasy football league. What is RW PRO?* A full season of fantasy football power tools designed to make winning easy and fun.* Year-round NFL player analysis.* Exclusive live off-season coverage from all major NFL scouting events.Support this podcast at — https://redcircle.com/rosterwatch-podcast/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Week 1 of the NFL Preseason is in the books, and we're breaking down the biggest risers, fallers, and rookie performances you need to know about. From Shedeur Sanders and Jaxson Dart balling out, to Treyveon Henderson's blazing speed and RJ Harvey's explosive debut — we cover who's building hype and who's just giving us hope. Injury updates include Landon Dickerson, Jayden Reed, Rachaad White, Tyjae Spears, and more. Plus, our “Would You Rather” battles for Shedeur Sanders and Treyveon Henderson against some big-name NFL veterans. Don't miss our full rookie WR breakdown featuring Tetairoa McMillan, Emeka Egbuka, Jalen McMillan, and Luther Burden. Thank you for checking out the Show, be sure to follow and comment if you have any questions, we are always happy to answer any. Make sure to Like & Subscribe while your here.

Some real estate teams are growing even in down markets. And that is not because they have doubled headcount or dumped money into leads, but because they have doubled down on data, service, and systems. That is exactly what Courtney Gauchman, COO at Wilson Group in Massachusetts, has helped her team do. With a background in the beauty industry and over a decade of operational leadership, Courtney now leads the systems and strategy that have fueled the Wilson Group's growth, despite navigating one of the toughest markets in recent years. And what is her approach? Track everything, but focus only on what moves the needle. From managing three full-time operations staff to building custom dashboards in Sisu, Courtney ensures every agent has clarity on where their business comes from and how to grow it. “We basically attribute the 88 percent growth during three of the hardest years in real estate to the fact that we use Sisu,” says Courtney. In this episode, Brian sits down with Courtney to talk about what it takes to run a referral-based real estate business, how to keep agents productive without burnout, and why they are starting to build an operations-as-a-service company for agents who do not want to manage staff. They also discuss how operational clarity impacts culture, conversion, and client experience! Top Takeaways: (1:38) From salon management to real estate ops  (4:14) Why are salon pros thriving in real estate?  (6:40) Building a business vs. slinging homes (8:14) Growing 88% through post-sale follow-up (9:26) Sisu dashboards built for ROI (12:00) Deep conversations over cold calls  (14:34) $70M+ in referral-based volume (15:43) Setting the referral expectation early (18:57) Building a referral system inside Sisu (22:42) Custom accountability for agent success  (26:43) Turning rental data into buyer leads (31:41) Building an ops-as-a-service model from Sisu (35:50)  Reviewing past data to guide marketing   If you are still guessing where your next deal will come from, this one is worth a listen.   About Courtney Gauchman Courtney Gauchman is the COO of the Wilson Group, a Keller Williams team based in Massachusetts. She brings 12 years of operations experience and a background in real estate sales. At Wilson Group, she leads the development of systems that support both clients and agents. Outside of work, she enjoys family time, outdoor activities, and experimenting with espresso martinis.   Connect with Courtney: Instagram

Get actionable strategies for your business delivered weekly to your inbox. Subscribe to The FoundHer Files. No fluff. No gatekeeping. Just what works...because we're better together. SUBSCRIBE HERE.In this episode, Lindsay Pinchuk reflects on the journey of her podcast, Dear FoundHer..., as it approaches its 300th episode. She shares the evolution of the podcast into a supportive community for women entrepreneurs over 40, highlighting key lessons learned from her interviews with inspiring female founders. Lindsay emphasizes the importance of trusting one's intuition, staying true to one's mission, and the power of community in building successful businesses. She also offers personal reflections on her growth and the impact of the community on her life.Female Founded Businesses We Love mentioned in this episode: Odele Beauty: You can check out Founder, Lindsay Holden on the podcast, and make sure you show them some love.Shop Chunky: Check them out and show her some love.Adulting 101 Masterclass: Show her some love here.Rebecca Minkoff Frankie Mini Woven Tote: You can check out our conversation on the podcast here. Don't forget to show her some love.The Write Stop: Show her some love here.Resources + Links:SWEEP: How One Framework Helped Me Launch a Top 1% PodcastSubscribe to our weekly newsletter on Substack: The FoundHer FilesWant support, strategy, and a powerful network? Join the Dear FoundHer… ForumHave a question about growing without a budget or landing partnerships? DM Lindsay @dearfoundher on Instagram.If you enjoyed this episode:Please rate, review, and share Dear FoundHer... with another woman business owner who needs to hear this. And don't forget to subscribe so you never miss a no-fluff, all-strategy conversation. Hosted on Acast. See acast.com/privacy for more information.

Sean is solo for this hour. He breaks down his biggest takeaways from yesterday's Texans practice, assesses Clint Stoerner's theory about CJ Stroud's workload, and goes through the day's Headlines.

The Buffalo Bills are back at it in St. John Fisher, and we're breaking down all the key storylines from Week 1 of training camp! In this episode, we dive into:

What happens when you stop building your real estate business the way everyone tells you to and start building it around who you really are? On this episode, JD Reese shares how he rebuilt from that exact moment and what came next. He takes us inside Genuine Real Estate Group, one of the most consistent teams in Southern Utah, where 60 listings stay active and under contract, and agent turnover is nearly zero. He breaks down how they keep that kind of performance steady without burning out. From pricing strategy and emotional sellers to tracking accountability and team culture, JD gets into the decisions that drive results. “You've got to be the best house and the best offering in the neighborhood,” he says. But that's just the beginning. JD also unpacks how his team uses tools like Sisu's new product “Battr”, to track every step of the lead journey, flag breakdowns, and stay focused on what actually moves the needle. “It's not about more leads. It's about calling fewer leads more.” No outbound recruiting. No scripts. Just structure, speed, and real coaching. “If you're not converting anything into your name, your database is too small.” You'll hear how they onboard new agents, use mentorship to drive growth, and create space for real conversations instead of surface-level tactics. Top Takeaways: (1:56) Listings sitting longer & seller strategy (3:22) Pricing strategy that actually works (7:26) Impact of interest rates dropping to 5% (10:31) Lead gen strategy for every listing (11:26) Sisu's new product “Battr” (12:29) Tracking lead life from start to close (18:24) Lead spending vs. accountability (20:45) Training agents without scripts (23:53) Using Sisu dashboards to coach agents (28:05) Picky recruiting & low team turnover (31:05) Builder partnerships through lead strategy (33:58) Real estate and Porsche passions (36:47) The 1% rule for long-term growth If you're trying to build a business that lasts and lead in a market where most are pulling back, this one's worth your time. Hit play and dive in. About JD Reese JD Reese is the founder and CEO of The Genuine Group, a real estate team based in Southern Utah. With nearly a decade in the industry, he's facilitated close to 1,000 transactions and continues to stay active in both sales and team leadership. Raised in St. George, JD brings local expertise and a strong focus on systems, follow-up, and agent development. He's also a licensed general contractor and runs his business with a hands-on, practical approach. Connect with JD Reese: LinkedIn  JD Reese - Instagram The Genuine Group - Instagram

Day 1 of Atlanta Falcons training camp is in the books, and there were plenty of takeaways on offense, defense, and roster moves. Scott Kennedy gets into all of it on a special Friday edition of the Falcons Podcast. The Falcons Podcast streams live every Monday and Wednesday at 8:35 a.m. EST ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/c/scottkennedy?sub_confirmation=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Looking for a New Home in the Atlanta Area? Ryann Kennedy Homes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ryannkennedy.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For More Atlanta Falcons News: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.si.com/nfl/falcons/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ The Falcons Podcast: Spotify -⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://open.spotify.com/show/4Sa2BYyM3pLAV78VXAb1Cs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ iTunes - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-falcons-podcast/id1625096227?uo=4⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠iHeart - https://www.iheart.com/podcast/53-the-falcons-podcast-97509849/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #Falcons #atlantafalcons #RiseUp Learn more about your ad choices. Visit megaphone.fm/adchoices

Catch #TrendingintheAM on the #STTSportsNetwork -- LIVE today at 8am --> https://www.youtube.com/live/hHUE_W_ktAQ?si=ZKNseAGwEwuZNafJ Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Altitude Advantage, team reporter Elisa Hernandez and lead writer Aric DiLalla discuss the Broncos' start to training camp, their mentality heading into the season and what's stood out from the pair of acclimation practices. Intro + reviewing the Broncos' mentality entering camp (00:00-14:01) Top takeaways from the Broncos' acclimation practice (14:02-20:23) Want more of Altitude Advantage? Subscribe on Apple Podcasts, Spotify, TuneIn, Stitcher or wherever you get your podcasts. Make sure to leave a rating and review or a comment if you're watching on YouTube.See omnystudio.com/listener for privacy information.

Top Takeaways from the Coccydynia Symposium (Flash Sale!)We just wrapped the Coccydynia Symposium, bringing together the world's leading experts on persistent tailbone pain.In this episode, Nicole shares her biggest takeaways from each speaker, including:

In this episode of Volunteer Nation, Tobi Johnson dives into the key findings from the Giving USA 2025 report and uncovers the powerful link between volunteerism and philanthropy. Tobi explores how individual donors and volunteer leaders are shaping the future of nonprofit fundraising, and why community support has never been more essential. Whether you're a nonprofit leader, volunteer coordinator, or board member, you'll walk away with actionable tips for harnessing the power of volunteers to boost giving and deepen your organization's impact. Full show notes: 170. My Top Takeaways from Giving USA 2025 Giving USA - Episode Highlights [01:36] - Introduction to Philanthropy and Volunteerism [03:07] - Key Insights from the Giving USA 2025 Report [06:17] - Deep Dive into Philanthropy Data [10:44] - Volunteerism's Role in Philanthropy [24:10] - Engaging Younger Generations in Philanthropy [28:06] - Breaking Down Silos for Better Community Engagement  Helpful LinksVolunteer Management Progress Report  VolunteerPro Impact Lab  Volunteer Nation Episode #71: Partnering with Funders to Support Volunteer Engagement with Jane Justis & Betsy McFarland  Volunteer Nation Episode #158: Nonprofit Capacity Building with the Community Foundation for a greater Richmond  Volunteer Nation Episode #60: Giving Circles and Collective Philanthropy with Sara Lomelin  Volunteer Nation Episode #163: New Research from Points of Light with Jennifer Sirangelo  VolunteerPro Blog, 5 Surprising Myths About Volunteers and Donors  Giving USA 2025  Thanks for listening to this episode of the Volunteer Nation podcast. If you enjoyed it, please be sure to subscribe, rate, and review so we can reach more people like you who want to improve the impact of their good cause. For more tips and notes from the show, check us out at TobiJohnson.com. For any comments or questions, email us at WeCare@VolPro.net.

Welcome to Insiders Rewind — Recapping June! ✅ Episodes from June: 229 - What's Trending in Commercial Insurance? 230 - Untapped Talent: How a VA Can Help You Grow 231 - The Biggest Marketing Mistakes We See 232 - From Authority to Ownership: Leadership from the Trenches A HUGE shout to our sponsors! Coalmarch: Digital strategies and conversion-driven websites are waiting for you and it's time for a free month! Visit https://www.coalmarch.com/podcast to claim yours! PestSure: Providing pest industry specific insurance for your business and insuring the future of pest control. VoiceForPest: Designing and implementing unparalleled integrated voice solutions for home service companies of any size from coast to coast. https://www.voiceforpest.com/podcast/ We'd love to hear from you. Drop a comment, leave a review on Apple Podcasts or Spotify, and connect with us on social media @PMPIndustryInsider.    Listen On: Spotify | Apple Podcasts | YouTube | Google Podcasts

" Challenging yourself is how you produce growth in your own life." Countless late nights, occasional tears, and many great conversations later, we did it. We made it to 100 episodes of REPOD! We've had so many incredible guests come on the show, fully willing to share the secret sauce to their success. These guests have been a treasure trove of creative inspiration. From discussing how to create immersive sets, to tricks for directing a player's attention, from how to effectively market your business to creating puzzles, our guests didn't gatekeep or pull their punches. To celebrate, we're taking a look back through the archives and picking some noteworthy clips. These were all things our guests said that really resonated with us – personally, professionally, or on a creative level. Each of these clips fundamentally changed how we think about something. Maybe it gave us a new perspective on leadership, like Elan Lee's clip about "other people's work." Or perhaps it was Christine Barger going against industry norms by allowing filming in her escape room. Others were more philosophical, like Alexander Gierholz's musings on the dissonance of escapism. Many of these clips helped shape the way we think about immersive design, such as Linda Klein talking about "experiential mixers" or Tommy Honton's "adrenaline map." It's been an amazing 100 episodes of Reality Escape Pod. I hope our guests have also inspired you in your creative journey. And if they did, we'd love to hear about it. Let us know if there's anything we missed that especially resonated with you. Thank you all for listening and for all your support!   Episode Sponsors Thank you to our sponsors: Weldwood Marketing, Buzzshot, COGS by Clockwork Dog, and Patreon supporters like you.    Weldwood Marketing Maximize your online presence with Weldwood Marketing. It's a one-stop shop for digital marketing—specializing in web design, SEO, online ads, and best business practices. They can even manage all your integrations so you can track the customer journey from clicking on an ad to booking your game. Let Weldwood help unlock more money for your business. Special offer exclusively for REPOD listeners: Weldwood rarely offers discounts, but they did for us. REPOD listeners get 15% off Marketing Services for the first 3 months, PLUS $750 off escape room websites. Schedule your Discovery Call and mention REPOD in the notes! Visit weldwoodmarketing.com/repod to learn more about this exclusive offer.   Buzzshot Buzzshot is Escape Room Software, Powering Business Growth, Player Marketing, and improving the Customer Experience. They offer an assortment of pre and post game features including robust waiver management, branded team photos, and streamlined review management for Yelp, TripAdvisor, Google Reviews, and Morty. Buzzshot now has integration with the other REPOD sponsors: Morty and COGS. Special Offer for REPOD Listeners: REPOD listeners get an extended 21-day free trial plus 20% off your first 3 months, with no set-up fees or hidden charges. Visit buzzshot.com/repod to learn more about this exclusive offer.   COGS COGS by Clockwork Dog is an easy to use software/ hardware platform for running interactive events, including escape rooms, and other immersive experiences. They have plug & play hardware that seamlessly integrates with their software so you can create a show with lighting and sound cues without having to write a single line of code. Map all kinds of inputs to outputs by building up simple logic steps which determine what you want to happen and when. Special Offer for REPOD Listeners: REPOD listeners can get the COGS Starter Set for only $130 + free shipping to the USA. This bundle is usually valued at $257. You can learn more and purchase your Starter Set at cogs.show. Use code REPOD at checkout.   Become a Patron Today! Supporitng us on Patreon helps to fund our work, pay our team, and it grants you access to an incredible library of bonus content including:  The REPOD Bonus Show The Spoilers Club The Travelogue Series Thank you to all of our ongoing supporters

Top 5 Gay-Friendly Places in Mexico to RetireIn this episode of Queer Money®, we continue our global search for the best places for LGBTQ+ folks to retire — and this week, we're diving into México lindo. From beach towns to colonial gems, we're counting down the top 5 gay-friendly cities in Mexico for retirement based on affordability, safety, community, and queer inclusivity.Find out why cities like Puerto Vallarta, Guadalajara, and San Miguel de Allende made the list, what each has to offer the LGBTQ+ community, and how much it costs to live there comfortably. Whether you want a bustling metropolis or a lakeside haven, Mexico may just be your retirement paradise.

At the New York Life Investments' Global Investor Forum, one theme was loud and clear: the global investment landscape is undergoing structural change. And rather than “wait and see” how these structural changes play out, our gathering of global investors focused on action, from assessing geopolitical risk to finding quality across asset classes. In this episode, Lauren Goodwin and Julia Hermann explore allocators' fresh look at global diversification. 

In this engaging and insightful conversation, Jeannette Linfoot speaks with Christina Brooks, founder of Ruebik, a B Corp-certified executive search firm on a mission to reshape diversity and inclusion in leadership. Christina shares her personal journey from embracing diversity as a core life mission in 2018 to building Ruebik—a company that challenges traditional recruitment norms by prioritizing values, cultural intelligence, and mentorship. They discuss the pervasive issue of diversity fatigue in organizations, the tangible commercial benefits of diverse leadership, and how innovative approaches to recruitment can foster truly inclusive cultures. The episode also explores how accessibility innovations and technology have connected communities, especially during COVID, and how personal struggles can be reframed as strengths. Christina and Jeannette dive deep into the courage required for bold leadership, the critical role of mentorship, and the vision for a more equitable business world. Top Takeaways• Diversity became Christina's mission in 2018.• Rubik aims to tackle diversity in executive search.• Traditional exec search perpetuates existing power structures.• Rubik is a B Corp focused on profit, people, and planet.• Candidates should be assessed on values, not just skills.• Diversity fatigue remains a real challenge for organizations.• Diverse boards deliver better financial outcomes.• Cultural intelligence is key to understanding community needs.• B Corp certification sharpens societal impact focus.• Creating inclusive cultures enhances experiences for all.• Accessibility innovations benefit broader audiences.• COVID tech connected isolated individuals like Christina’s mother.• Diversity in leadership is essential for community growth.• Entrepreneurship lacks a playbook; each decision is unique.• Mentorship is crucial for overcoming business challenges.• Struggles can be reframed as qualifications for success.• Grace is essential for self-care and leadership.• Bravery involves speaking uncomfortable truths.• Creating opportunities for others is a vital leadership trait. Sound Bites"Diversity became my mission in 2018.""Rubik aims to tackle diversity in executive search.""Diverse boards lead to better financial performance.""A truly inclusive culture is fascinating.""Zoom and Teams connected my 80-year-old mother.""We are all perfectly imperfect.""The best talent is not just in the M25.""The puzzle is solved when all sides are equal.""Your struggles are not your limitations.""Bravery is speaking truth to power.""Don't just climb the ladder, create an elevator.""Embracing failure is a powerful gift." Chapters00:00 – The Mission of Diversity02:56 – Building Rubik: A New Approach to Executive Search06:11 – Disrupting Traditional Recruitment Practices09:03 – Innovative Mentorship Programs12:06 – The Importance of Values in Recruitment14:54 – Addressing Diversity Fatigue17:54 – The Commercial Value of Diversity21:06 – B Corp Certification and Its Impact23:57 – Focusing on Cultural Intelligence26:52 – Future Directions for Diversity and Inclusion31:26 – The Importance of Inclusive Culture34:55 – Innovations Benefiting Diverse Communities36:45 – Global Leadership and Hope41:53 – Challenges of Entrepreneurship46:24 – The Role of Mentorship47:55 – Future Vision for Rubik51:52 – Personal Struggles as Qualifications58:35 – Embracing Grace in Leadership59:59 – Defining Brave Bold Brilliant About the HostJeannette Linfoot is a highly regarded senior executive, property investor, board advisor, and business mentor with over 30 years of global experience across travel, leisure, hospitality, and property sectors. Known for her down-to-earth leadership style, Jeannette champions diversity and inclusion and is passionate about nurturing talent to help others reach their full potential. She hosts Brave Bold Brilliant to inspire and equip leaders to drive impactful change. [Follow Jeannette Linfoot]Website: https://brave-bold-brilliant.com/LinkedIn: https://uk.linkedin.com/in/jeannettelinfootYouTube: https://www.youtube.com/@braveboldbrilliantInstagram: https://www.instagram.com/jeannette.linfoot/Facebook: https://www.facebook.com/jeannette.linfoot/Podcast: https://podcasts.apple.com/gb/podcast/brave-bold-brilliant-podcast/id1524278970 About the Guest – Christina BrooksChristina Brooks is the founder of Ruebik, a B Corp-certified executive search firm dedicated to disrupting traditional recruitment by centering diversity, values, and cultural intelligence. Since making diversity her mission in 2018, Christina has worked to challenge entrenched power structures in executive search and create pathways for more inclusive leadership. She is passionate about mentorship, innovation, and fostering workplaces where diverse voices thrive. Her approach emphasizes the commercial value of diversity alongside its societal importance, blending business success with a strong ethical framework.

Shan and RJ discuss their confidence levels in each of the Cowboys' offensive position groups, why Micah Parsons strapped on his helmet at minicamp, and take an inside look at new cornerback Kaiir Elam's performance in minicamp. The K&C Masterpiece attempts to describe the worst-case scenario for the Dallas Cowboys' 2025 season. Bryan Broaddus shares his top takeaways from Day 2 of Cowboys minicamp, including how George Pickens was being used on the offense adjacent to CeeDee Lamb, what guard combinations were being used, and how Kaiir Elam had another standout day. Plus, Fox Sports' David Helman drops by to discuss Micah Parsons' contract and if he's interested in bringing in Von Miller.

Shan and RJ discuss their confidence levels in each of the Cowboys' offensive position groups, why Micah Parsons strapped on his helmet at minicamp, and take an inside look at new cornerback Kaiir Elam's performance in minicamp. The K&C Masterpiece attempts to describe the worst-case scenario for the Dallas Cowboys' 2025 season. Bryan Broaddus shares his top takeaways from Day 2 of Cowboys minicamp, including how George Pickens was being used on the offense adjacent to CeeDee Lamb, what guard combinations were being used, and how Kaiir Elam had another standout day. Plus, Fox Sports' David Helman drops by to discuss Micah Parsons' contract and if he's interested in bringing in Von Miller.

Shan and RJ discuss their confidence levels in each of the Cowboys' offensive position groups, why Micah Parsons strapped on his helmet at minicamp, and take an inside look at new cornerback Kaiir Elam's performance in minicamp. The K&C Masterpiece attempts to describe the worst-case scenario for the Dallas Cowboys' 2025 season. Bryan Broaddus shares his top takeaways from Day 2 of Cowboys minicamp, including how George Pickens was being used on the offense adjacent to CeeDee Lamb, what guard combinations were being used, and how Kaiir Elam had another standout day. Plus, Fox Sports' David Helman drops by to discuss Micah Parsons' contract and if he's interested in bringing in Von Miller.

CLNS Media's Taylor Kyles, 98.5 The Sports Hub's Alex Barth, and Pats Pulpit's Brian Hines team up for a special crossover episode of Patriots Daily and Patriots Beat, recapping Day 2 of Patriots Veteran Minicamp. The trio breaks down top takeaways from each position group, including Drake Maye's development, what Stefon Diggs had to say today, the state of the offensive line, standout defenders, and early notes on special teams. Join Patriots Press Pass' channel membership to get access to our BONUS content:

CLNS Media's Taylor Kyles, 98.5 The Sports Hub's Alex Barth, and Pats Pulpit's Brian Hines team up for a special crossover episode of Patriots Daily and Patriots Beat, recapping Day 2 of Patriots Veteran Minicamp. The trio breaks down top takeaways from each position group, including Drake Maye's development, what Stefon Diggs had to say today, the state of the offensive line, standout defenders, and early notes on special teams. Join Patriots Press Pass' channel membership to get access to our BONUS content:

The Broncos have wrapped up another round of OTAs. Who stood out at practice yesterday? Which rookies are making their mark? And how does newly-acquired Evan Engram look so far? Plus, a look at the exciting finish to Game 1 of the NBA Finals. Eric and Bruce break it all down on a Friday edition of Hot Takes!

Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who are not transplant eligible.  Starting with LBA9500, this study was conducted in patients with completely resected stage III or IV malignant melanoma and compared the combination of relatlimab plus nivolumab versus nivolumab alone in this population. The study, named the RELATIVITY-098 trial, was presented by Dr. Georgina Long from the University of Sydney, Australia. In her introduction to the study, Dr. Long explained that the current standard of care for adjuvant therapy of resected stage III/IV melanoma is with PD-1 monotherapy with nivolumab, but that about 50% of patients will suffer from a subsequent relapse. In the first-line setting in patients with advanced or unresectable melanoma, the combination of nivolumab with the LAG-3 inhibitor, relatlimab, has been previously shown to improve progression-free survival in the RELATIVITY-047 trial. The current study evaluated this same combination in the adjuvant setting. More than 1,000 patients from 24 countries were randomized to receive either nivolumab alone (546 patients) or the combination of nivolumab with relatlimab (547 patients). Both treatments were given for a maximum of 1 year or until progression of disease, unacceptable toxicity, withdrawal, or death. Various biomarker studies were also undertaken including LAG-3 and PD-1 expression on CD8-positive T cells. The primary endpoint of the study was relapse-free survival, and Dr. Long reported that this was the same in both arms of the study. For example, at 24 months, the relapse-free survival was 64% in the monotherapy arm compared with 62% in the combination arm. The hazard ratio was 1.01 and the P value was 0.928. Metastasis-free survival was also identical in both arms. No benefit was observed for the combination in any of the prespecified subgroups. No new toxicity signals emerged compared with the RELATIVITY-047 trial. Interestingly, the baseline surface expression of LAG-3 and co-expression of LAG-3 and PD-1 on CD8 T cells in the 098 adjuvant trial were lower than in the 047 advanced disease trial, perhaps explaining why the combination did not confer benefit over nivo alone in the adjuvant setting. This is an important result, demonstrating that results from one clinical setting cannot always be extrapolated to another. Although the combination has gained some use in the adjuvant setting, this study clearly demonstrates that more drug in this situation is no better and that monotherapy remains the current standard of care. Results from the AMPLITUDE trial for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes, in LBA5006, were presented today by Dr. Gerhardt Attard from University College London, UK. This international, multicenter study evaluated the combination of the selective PARP inhibitor, niraparib, in combination with abiraterone acetate and prednisone. The same combination has been previously shown to improve outcomes in castration-resistant metastatic prostate cancer harboring BRCA mutations in the MAGNITUDE study. The current trial included patients with castration-sensitive disease with HRR mutations including BRCA1/2. Six hundred and ninety-six patients were randomized between niraparib, abiraterone, and prednisone plus androgen deprivation therapy, or the same combination with placebo instead of niraparib. Permitted prior therapies included no more than 6 months of prior androgen deprivation therapy and the use of docetaxel, or prior palliative radiation therapy. The primary endpoint of the study was radiographic relapse-free survival. Dr. Attard reported that the risk for radiographic progression-free survival in the whole population was significantly reduced by 37% with niraparib and abiraterone acetate plus prednisone compared with the placebo arm. The radiographic progression-free survival risk reduction with niraparib in the prespecified BRCA1/2 subgroup was 48% and reached statistical significance compared with the placebo arm. The secondary endpoint of time to symptomatic progression was also improved with niraparib in the HRR population and the BRCA1/2 subgroup. There was a trend for overall survival favoring the niraparib combination. However, the overall survival data were immature at this first interim analysis and did not yet reach statistical significance. No new safety concerns emerged with the toxicity data consistent with the MAGNITUDE study. Less than 5% more of the patients on the experimental arm discontinued treatment in comparison to the control arm. The authors conclude that the AMPLITUDE study results support the use of niraparib, abiraterone, and prednisone as a new treatment option for patients with metastatic castration- sensitive prostate cancer and BRCA and homologous recombination repair gene alterations. The results certainly support this conclusion and are potentially practice-changing. Turning to hematologic malignancies, my final selection from today's presentations is Abstract 7504, presented by Dr. Hang Quach from St Vincent's Hospital, Melbourne, Australia, and describes a novel combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed multiple myeloma who are not transplant-eligible – the so-called MagnetisMM-6 trial part 1. Elranatamab is a novel bispecific T-cell engaging antibody directed against BCMA and CD3, which has previously been approved for certain patients with relapsed and refractory multiple myeloma. In the present study, this was combined with lenalidomide and daratumumab in newly diagnosed patients. The report today describes the dose-finding phase of this study, which was part 1, specifically addressing so-called dose level ‘G', comprising elranatamab 76mg subcutaneously every 4 weeks plus daratumumab 1800mg subcutaneously and lenalidomide 25mg given orally. Thirty-seven patients were entered at this dose level, of whom 32 were on treatment at the time of analysis. Early response data show an overall response rate of 97.3%. With median follow up of 7.9 months, the current CR rate is 27% with a VGPR rate of almost 68%. The most frequent toxicities were hematologic, with neutropenia observed in 75%. Some cytokine release syndrome was observed in about 60% of patients, but none was greater than grade 2. The authors conclude that this combination is active in untreated multiple myeloma, with manageable toxicity and evidence of responses which appear to deepen over time. The dose-finding component of this trial is continuing and will subsequently progress into a phase 3 trial based on the data from the current study. This will compare daratumumab plus lenalidomide with the same combination plus elranatamab in previously untreated patients. That concludes our special coverage from the 2025 ASCO Annual Meeting. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 4 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. Today's selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation. The first of these studies, Abstract 8006, was presented by Dr. Luis Paz-Ares from the University Hospital [October 12] in Madrid, Spain, and reports the primary results of the IMforte trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer. Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor [that is] already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials. The IMforte trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin. The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups. This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease. Next up is LBA5500, presented by Dr. Sven Mahner from LMU University in Munich, Germany. This describes the results of the TRUST study, a randomized trial of upfront surgical therapy in advanced ovarian cancer. As background, total macroscopic tumor resection with maximal effort cytoreductive surgery is the cornerstone of treatment in patients with advanced ovarian cancer. The optimal timing of such surgery remains controversial, whether it's more beneficial as a primary cytoreductive surgery before chemotherapy or in the form of interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy. Previous studies have addressed this issue, but results have been confounded by issues of patient and center selection. The TRUST study is a randomized, international, multicenter phase 3 trial that compares the outcomes of the timing of surgery in surgically fit patients with seemingly resectable FIGO stage IIIB/IVB ovarian, tubal, and peritoneal carcinoma. To ensure consistent and adequate surgical quality, participating centers in the trial were required to obtain accreditation and undergo an onsite quality assurance review. This included assessment of infrastructure, surgical proficiency, complete resection rates, and surgical volume. Seven hundred and ninety-seven patients with advanced ovarian cancer were randomized to undergo surgery prior to therapy with 6 cycles of carboplatin and paclitaxel along with bevacizumab and a PARP inhibitor, or to have the surgery between the third and fourth cycle of the same systemic therapy. Of the initial 797 patients, 688 comprised the intent-to-treat population, of whom 345 received primary cytoreductive surgery and 343 received neoadjuvant chemotherapy followed by interval cytoreductive surgery.  The results show that patients undergoing primary surgery had significantly improved progression-free survival compared with those who had interval cytoreductive surgery (median progression-free survival was 22.1 months versus 19.7 months). No difference in overall survival was observed between the 2 arms of the study.  This is the first study to show a benefit for primary cytoreductive surgery, although the progression-free survival improvement was not reflected in an overall survival difference. A subgroup analysis for patients who underwent complete cytoreduction suggests a progression-free survival and survival benefit, although it isn't clear to me that the study was powered for this endpoint. Nevertheless, these are very difficult studies to perform, and the investigators should be congratulated for this robustly conducted clinical trial. Today's final abstract is 1504, presented by Dr. Hermioni Amonoo from Harvard Medical School. The trial evaluated BMT-VR, a virtual reality psychosocial intervention for patients undergoing bone marrow transplantation. This randomized trial included adult patients undergoing autologous and allogeneic transplantation. The BMT-VR platform included, among others, modules addressing psychoeducation, coping, acceptance, and gratitude. BMT-VR patients were provided with VR headsets and completed all modules during their hospitalization. Patient-reported outcomes were then assessed at 2, 4, 12, and 24 weeks post-BMT. Use of the VR tool was tracked during hospitalization. Control patients received usual care during their hospital stay and were then assessed at the same intervals post-BMT.  Eighty evaluable patients were randomized, 39 to BMT-VR and 41 to usual care. Completion rates for the BMT-VR modules were high [at] around 70-75%.  Patients who received the BMT-VR intervention experienced significantly improved anxiety, quality of life, and coping at 4 weeks post-BMT. In the longer term, sustained benefits were seen at 24 weeks for some endpoints including quality of life, with some benefits, including for depression and PTSD symptoms, improving longitudinally over the study period. These data are preliminary and will need to be confirmed in larger multicenter studies, but this trial demonstrates the feasibility of using virtual interventions in our patients and also provides intriguing preliminary data that they may be effective. Thanks for listening to today's report and I hope you will join me again tomorrow to hear more top takeaways from the final day of ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:     Dr. John Sweetenham       Follow ASCO on social media:      @ASCO on Twitter     @ASCO on Bluesky     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. John Sweetenham:     No relationships to disclose 

Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 3 of the 2025 ASCO Annual Meeting. Today's selection features studies addressing the treatment of advanced renal cell carcinoma and 2 studies exploring novel approaches in non-small cell lung cancer. My disclosures are available in the transcript of this episode. The first abstract is number 4505. This study, led by Dr. Toni Choueiri of the Dana-Farber Cancer Institute, describes the final analysis of the CheckMate 214 trial, which compared the combination of nivolumab and ipilimumab with sunitinib for the first-line treatment of advanced renal cell carcinoma. The ipi-nivo combination is approved for the frontline treatment of intermediate and poor-risk advanced renal cell carcinoma based on the primary analysis of the CheckMate 214 trial, which demonstrated a higher response rate and longer overall survival compared with sunitinib. Today's presentation provided the final safety and efficacy results for the trial with long-term follow-up of more than 9 years.  The intent-to-treat (ITT) population in this trial comprised 550 patients randomized to nivo and ipi versus 546 who received sunitinib. The final analysis showed sustained long-term benefit for the combination therapy. Patients given nivolumab plus ipi had a 29% reduction in the risk for death compared with sunitinib. For patients with intermediate or poor-risk disease, there was a 31% reduction in the risk of death.   The probability of remaining in response through 8 years was more than doubled with nivolumab plus ipilimumab versus sunitinib in the ITT population at 48% versus 19%, and in the intermediate and poor-risk population at 50% versus 23%. The other important observation is that patients with favorable-risk disease appeared to have a 20% reduction in the risk for death at 9 years and more durable responses. This suggests a possible delayed benefit for ipi and nivo in this group since these differences were not seen in the earlier analysis.   No new safety signals emerged with longer follow-up, and the results confirm the use of ipi and nivo as a standard front-line combination therapy in this disease. Since this combination has been in widespread use for some years, the results are not surprising although the subgroup analysis suggesting benefit in favorable-risk patients is likely to inform practice in the future.   Today's second abstract is number is 8506, which was presented by Dr. Tony Mok from the Chinese University of Hong Kong, describing results from the phase 3 HERTHENA-Lung02 trial. This trial compared the antibody-drug conjugate patritumab deruxtecan with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following a third-generation tyrosine kinase inhibitor (TKI).  Patritumab deruxtecan, also known as HER3-DXd, comprises a fully human anti-HER3 IgG3 monoclonal antibody conjugated to a topoisomerase 1 inhibitor payload, and showed activity in a previous phase 2 trial in patients relapsing after EGFR TKI and chemotherapy.   In this phase 3 study, this agent was compared with platinum-based chemotherapy in eligible patients with an EGFR-activating mutation who had previously received 1 or 2 EGFR TKIs, at least one of which was a third-generation drug, with relapse or progression after this therapy. Five hundred and eighty-six patients were enrolled, with progression-free survival as the primary endpoint.  The primary analysis showed a 9-month progression-free survival of 29% for the experimental arm compared with 19% for platinum-based chemotherapy, for a hazard ratio of 0.77 and a P value of 0.011. With higher progression-free survival rates at 6 months and 12 months, HER3-DXd also had a better objective response rate (35.2% versus 25.3%) compared with platinum-based chemotherapy (PBC), and HER3-DXd also extended intracranial progression-free survival compared with PBC in patients with brain metastases, with a hazard ratio of 0.75. Grade 3 or more treatment-related adverse events occurred in 73% of patients treated with HER3-DXd and 57% of patients who received PBC. HER3-DXd had a higher rate of grade or more 3 thrombocytopenia, and drug-related interstitial lung disease occurred in 5% of patients in the HER3-DXd arm.   The follow-up will need more time to mature since no overall survival data are currently available, but definitely an agent to watch with interest. Moving on to today's final abstract, 8500, was presented by Dr. Pasi Jänne from the Dana-Farber Cancer Institute, describing results from the phase 2 portion of the KRYSTAL-7 study. This study is exploring the use of a potent KRAS inhibitor, adagrasib, in combination with pembrolizumab in patients with advanced or metastatic KRASG12C- mutated non-small cell lung cancer.  Adagrasib has already received accelerated approval in the U.S. for previously treated locally advanced or metastatic NSCLC with a KRASG12C mutation. A previous report from the KRYSTAL-7 study demonstrated encouraging activity in combination with pembrolizumab in the frontline setting for this patient group who also had more than 50% expression of PD-L1. The presentation today described efficacy and safety data for this drug combination across all PD-L1 expression levels.  One hundred and forty-nine patients with a median age of 67 years were treated with the combination, 104 of whom had PD-L1 expression level results available, representing the so-called biomarker population in this trial. The overall response rate for the entire study population was 44%. In the biomarker population, the overall response rate ranged from 36% in those with less than 1% PD-L1 expression to 61% for those with more than 50% expression. For all patients, the median response duration was just over 26 months, and the median progression-free and overall survival rates were 11 and 18.3 months respectively.    For the biomarker population, the median progression-free and overall survival were highest in those patients with more than 50% PD-L1. No new safety issues emerged from this analysis; the most frequent toxicities were nausea, diarrhea, and increases in transaminases. Immune-related toxicities included pneumonitis, hypothyroidism, and hepatitis. These are important results and the results of the phase 3 portion of KRYSTAL-7, which compares first-line therapy with adagrasib plus pembro versus pembro alone in the KRASG12C mutated/PD-L1 more than 50% group, will be informative. For those patients with lower levels of PD-L1 expression, the authors suggest that the treatment escalation may be beneficial, possibly including the addition of chemotherapy.  That concludes today's report. Thanks for listening and I hope you will join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

The San Francisco 49ers kicked off OTA's today and thus were sharing the latest takeaways from the practice including the return of Christian McCaffrey, Ricky Pearsall's injury and the first glimpse of Brock Purdy after signing a massive contract extension.Plus, we reveal some key absences and detail some of the days winners and including Jacob Cowing, Renardo Green and Mykel Williams.

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

In this episode of RNT Fitness Radio, we sit down with Professor Jane Ogden, a leading health psychologist and professor at the University of Surrey. With over three decades of research in eating behavior, weight management, and women's health, Jane has been at the forefront of understanding the psychological drivers behind our relationship with food. Her expertise dives deep into the learned associations, cultural influences, and individual perceptions that shape our eating habits. Join us as we explore the psychology of eating, the barriers to sustainable weight loss, and practical strategies for long-term health transformation.   Chapters: 00:00 Introduction to Health Psychology and Eating Behavior 02:35 The Complexity of Hunger and Eating Triggers 04:37 Understanding Emotional and Social Eating 10:18 The Importance of Meal Structure 12:39 Intuitive Eating vs. Structured Eating 17:58 Navigating Social Pressures and Eating Choices 20:47 Navigating Truth and Lies in Self-Care 22:20 Psychological Barriers to Healthy Living 24:48 The Impact of Childhood Food Associations 26:06 The Evolution of Nutritional Advice 28:01 Breaking the All-or-Nothing Mindset 30:59 Sustainable Caloric Restriction Strategies 32:05 The Importance of Planned Eating 34:23 Managing Emotional Eating Through Planning 36:42 The Role of Biology vs. Psychology in Weight Loss 37:39 Top Takeaways for Managing Eating Behaviors   Next steps:  1) Apply for 1-1 coaching: https://www.rntfitness.co.uk/pro/   2) Take our quiz to see if you're ready for a transformation: http://www.rntfitness.co.uk/transform   3) Get our free book shipped to your door: https://bit.ly/tybtylform   4) Try our free 28 day fat loss accelerator: https://www.rntfitness.co.uk/transformation-accelerator  5) Optimum Nutrition: RNT20 for 20% off Connect with RNT Fitness:  Website  Facebook  Instagram  YouTube  Email  Connect with Akash:  Facebook  Instagram  LinkedIn 

Thinking about playing football at the next level? In this episode of The Gametime Guru Podcast, we dive deep into the real-life journey of Carl Pickens, from high school standout to Freshman All-American at Tennessee, to NFL Offensive Rookie of the Year with the Cincinnati Bengals. This conversation is essential listening for:

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Ray and JRich break down everything you need to know from NFC Rookie Mini Camps—highlighting which first-year players already stand out across the league. From top draft picks to under-the-radar names, we're tracking:

We're breaking down all the biggest stories and early standouts from AFC Rookie Mini Camps! Ray and JRich go team-by-team highlighting the rookies who are already making noise, adjusting quickly, or flashing long-term potential. From first-round picks to late-round sleepers, we're tracking who's turning heads and which storylines matter most.

Tommy Scoops is back with a vengeance ready to dive into all the biggest MLS talk like Mikal Bridges defending a last second shot. Gass and Tom dig into LAFC's Club World Cup hopes being brought back, your big questions from the MLS weekend, and of course an incredible upcoming round of USOC with some big Cupset potential.11:20 LAFC Club World Cup Play In Chance26:30 MLS Weekend Takeaways26:50 Austin FC Offensive Struggles31:15 Philly Center Mid Strength35:20 Revs Formation Change Success40:00 Top Homegrown Breakthroughs So Far In 202547:35 Vanney & LAG Struggles55:25 USOC Round Of 32 Preview1:05:48 Ice Cream Shop On KDB, Mueller & Some Homegrown Signings Soccerwise Live 2pm ET Every Tuesday/Wednesday/Thursday on Youtube/Twitch/Twitter

Fresh out of Beaver Stadium, we discuss who and what stood out during Penn State football's Blue-White Game. There are several storylines to review, along with a Saturday commitment from Syracuse receiver transfer Trebor Pena. Enjoy complete Penn State coverage anytime at Lions247.com. Follow the team on X: @Lions247 @TDsTake @danieljtgallen @tyler_calvaruso @MarkXBrennan. Follow or subscribe to the Lions247 Podcast on Spotify, Apple Podcasts, Stitcher, or wherever you get your podcasts. And watch every episode on YouTube. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In this deeply personal episode, Maggie shares her transformative experience attending a week-long Dr. Joe Dispenza meditation retreat. After struggling with chronic health issues for 18 months, she found herself immersed in a powerful environment of healing and connection. Maggie opens up about the challenges of intense meditation sessions, the beautiful community she discovered, and how this retreat pushed her beyond her comfort zone in unexpected ways. Whether you're familiar with Dr. Joe's work or simply curious about meditation's potential impact on health and mindset, this vulnerable conversation offers a glimpse into one person's journey through darkness into a more peaceful state. Click here to join vibe club  

Ever wonder what separates the Land Academy members who talk about success from the ones who make it happen? In today's episode of The Land Academy Show, Steven Jack Butala and Jill DeWit share the powerful real-life transformations happening behind the scenes—straight from recent consulting calls with ambitious Land Academy members. You'll hear stories of brand-new investors taking fast, focused action… seasoned pros making bold pivots to scale faster… and partners learning to streamline and delegate their way to $100K months. From spreadsheets to seller financing struggles, to 4am Zoom calls and website makeovers—this episode is packed with practical takeaways, inspiring wins, and a reminder that the right support can change everything. Whether you're just getting started or ready to level up, this one's for you.

The world is completely different than it was before ChatGPT.